Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for BioAge Labs, Inc. (BIOA:NASDAQ), powered by AI.
BioAge Labs, Inc. is currently trading at $22.19. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for BioAge Labs, Inc. on Alpha Lenz.
BioAge Labs, Inc.'s P/E ratio is -9.9.
“BioAge Labs, Inc. trades at a P/E of -9.9 (undervalued) with modest ROE of -27.1%.”
Ask for details →BioAge Labs Inc. is a biotechnology company focused on discovering and developing therapies that can enhance the human lifespan and address age-related diseases. By leveraging advanced technologies like artificial intelligence and genomics, BioAge Labs aims to pinpoint key molecular drivers of aging. Its approach involves identifying biological pathways that extend healthy lifespan, then discovering compounds that can influence these pathways to develop innovative treatments for age-associated conditions such as cancer, cardiovascular diseases, and metabolic disorders. BioAge Labs conducts research that spans various stages, from preclinical studies to early-stage clinical trials, frequently collaborating with leading scientific institutions and pharmaceutical partners. Operating within the biopharmaceutical industry, the company's work significantly impacts healthcare and wellness sectors by potentially altering age-related disease progression and improving quality of life for aging populations. As part of the burgeoning field of biotechnology focusing on longevity, BioAge Labs holds a notable place in the financial market by engaging in an area of medicine that combines cutting-edge bioinformatics with traditional biopharmaceutical research and development.
“BioAge Labs, Inc. trades at a P/E of -9.9 (undervalued) with modest ROE of -27.1%.”
Ask for details →BioAge Labs, Inc. (ticker: BIOA) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 62 employees. Market cap is $797M.
The current price is $22.19 with a P/E ratio of -9.89x and P/B of 2.93x.
ROE is -27.09% and operating margin is -1031.46%. Annual revenue is $9M.